CA2375908C - Highly selective norepinephrine reuptake inhibitors and methods of using the same - Google Patents
Highly selective norepinephrine reuptake inhibitors and methods of using the same Download PDFInfo
- Publication number
- CA2375908C CA2375908C CA002375908A CA2375908A CA2375908C CA 2375908 C CA2375908 C CA 2375908C CA 002375908 A CA002375908 A CA 002375908A CA 2375908 A CA2375908 A CA 2375908A CA 2375908 C CA2375908 C CA 2375908C
- Authority
- CA
- Canada
- Prior art keywords
- reboxetine
- disorder
- norepinephrine
- reuptake
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title abstract description 33
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 title description 17
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 claims abstract description 107
- 229960003770 reboxetine Drugs 0.000 claims abstract description 84
- 150000001875 compounds Chemical class 0.000 claims abstract description 34
- 239000003814 drug Substances 0.000 claims abstract description 24
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- CBQGYUDMJHNJBX-OALUTQOASA-N (2S)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine Chemical compound CCOC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 CBQGYUDMJHNJBX-OALUTQOASA-N 0.000 claims description 73
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 44
- 238000011282 treatment Methods 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 21
- 208000027520 Somatoform disease Diseases 0.000 claims description 17
- 208000019695 Migraine disease Diseases 0.000 claims description 12
- 206010027603 Migraine headaches Diseases 0.000 claims description 11
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 8
- 208000000094 Chronic Pain Diseases 0.000 claims description 5
- 208000001640 Fibromyalgia Diseases 0.000 claims description 5
- 208000002193 Pain Diseases 0.000 claims description 5
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 5
- 201000001916 Hypochondriasis Diseases 0.000 claims description 4
- 208000033039 Somatisation disease Diseases 0.000 claims description 4
- 208000022266 body dysmorphic disease Diseases 0.000 claims description 4
- 208000012839 conversion disease Diseases 0.000 claims description 4
- 208000027753 pain disease Diseases 0.000 claims description 4
- 208000016994 somatization disease Diseases 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 2
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 80
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract description 62
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract description 56
- 229960002748 norepinephrine Drugs 0.000 abstract description 56
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract description 56
- 230000002401 inhibitory effect Effects 0.000 abstract description 30
- 229940076279 serotonin Drugs 0.000 abstract description 29
- 230000000144 pharmacologic effect Effects 0.000 abstract description 17
- 208000020016 psychiatric disease Diseases 0.000 abstract description 15
- 230000008901 benefit Effects 0.000 abstract description 13
- 238000002360 preparation method Methods 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 241000282412 Homo Species 0.000 abstract description 2
- 208000035475 disorder Diseases 0.000 description 36
- 230000000694 effects Effects 0.000 description 35
- 230000005764 inhibitory process Effects 0.000 description 20
- 230000000966 norepinephrine reuptake Effects 0.000 description 18
- 230000002411 adverse Effects 0.000 description 15
- 230000000697 serotonin reuptake Effects 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 12
- 239000000935 antidepressant agent Substances 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 208000022170 stress incontinence Diseases 0.000 description 11
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 10
- 229940005513 antidepressants Drugs 0.000 description 10
- -1 ~i-hydroxybutyrate Chemical compound 0.000 description 10
- 230000003389 potentiating effect Effects 0.000 description 9
- 208000011688 Generalised anxiety disease Diseases 0.000 description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 8
- 208000012902 Nervous system disease Diseases 0.000 description 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 208000029364 generalized anxiety disease Diseases 0.000 description 8
- 239000002858 neurotransmitter agent Substances 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 208000019901 Anxiety disease Diseases 0.000 description 7
- 206010002942 Apathy Diseases 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 230000037328 acute stress Effects 0.000 description 7
- 230000036506 anxiety Effects 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 230000037326 chronic stress Effects 0.000 description 7
- 208000024732 dysthymic disease Diseases 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 208000028173 post-traumatic stress disease Diseases 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 6
- 206010006550 Bulimia nervosa Diseases 0.000 description 6
- 206010012374 Depressed mood Diseases 0.000 description 6
- 206010057852 Nicotine dependence Diseases 0.000 description 6
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 description 6
- 208000025569 Tobacco Use disease Diseases 0.000 description 6
- 208000012826 adjustment disease Diseases 0.000 description 6
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 5
- 206010021639 Incontinence Diseases 0.000 description 5
- 206010026749 Mania Diseases 0.000 description 5
- 206010053236 Mixed incontinence Diseases 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 5
- 208000028017 Psychotic disease Diseases 0.000 description 5
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 5
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 5
- 206010048010 Withdrawal syndrome Diseases 0.000 description 5
- 229960003914 desipramine Drugs 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000002483 medication Methods 0.000 description 5
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 5
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 208000000103 Anorexia Nervosa Diseases 0.000 description 4
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 description 4
- 208000020925 Bipolar disease Diseases 0.000 description 4
- 208000020401 Depressive disease Diseases 0.000 description 4
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 4
- 208000020358 Learning disease Diseases 0.000 description 4
- 102000010909 Monoamine Oxidase Human genes 0.000 description 4
- 108010062431 Monoamine oxidase Proteins 0.000 description 4
- 208000025966 Neurological disease Diseases 0.000 description 4
- 206010041250 Social phobia Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000001430 anti-depressive effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 208000026725 cyclothymic disease Diseases 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 230000002631 hypothermal effect Effects 0.000 description 4
- 201000003723 learning disability Diseases 0.000 description 4
- 208000024196 oppositional defiant disease Diseases 0.000 description 4
- 208000019906 panic disease Diseases 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 208000012672 seasonal affective disease Diseases 0.000 description 4
- 208000019116 sleep disease Diseases 0.000 description 4
- 208000012217 specific developmental disease Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000016686 tic disease Diseases 0.000 description 4
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 208000027691 Conduct disease Diseases 0.000 description 3
- 208000008967 Enuresis Diseases 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010033307 Overweight Diseases 0.000 description 3
- 206010036618 Premenstrual syndrome Diseases 0.000 description 3
- 208000020190 Schizoaffective and schizophreniform disease Diseases 0.000 description 3
- 201000001880 Sexual dysfunction Diseases 0.000 description 3
- 208000000323 Tourette Syndrome Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000008406 drug-drug interaction Effects 0.000 description 3
- 230000001544 dysphoric effect Effects 0.000 description 3
- 229960002464 fluoxetine Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000035987 intoxication Effects 0.000 description 3
- 231100000566 intoxication Toxicity 0.000 description 3
- 230000029849 luteinization Effects 0.000 description 3
- 229960004090 maprotiline Drugs 0.000 description 3
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 201000003631 narcolepsy Diseases 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- FDXQKWSTUZCCTM-UHFFFAOYSA-N oxaprotiline Chemical compound C12=CC=CC=C2C2(CC(O)CNC)C3=CC=CC=C3C1CC2 FDXQKWSTUZCCTM-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 231100000872 sexual dysfunction Toxicity 0.000 description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- IVWWFWFVSWOTLP-YVZVNANGSA-N (3'as,4r,7'as)-2,2,2',2'-tetramethylspiro[1,3-dioxolane-4,6'-4,7a-dihydro-3ah-[1,3]dioxolo[4,5-c]pyran]-7'-one Chemical compound C([C@@H]1OC(O[C@@H]1C1=O)(C)C)O[C@]21COC(C)(C)O2 IVWWFWFVSWOTLP-YVZVNANGSA-N 0.000 description 2
- WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 2
- CBQGYUDMJHNJBX-UHFFFAOYSA-N 2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine Chemical compound CCOC1=CC=CC=C1OC(C=1C=CC=CC=1)C1OCCNC1 CBQGYUDMJHNJBX-UHFFFAOYSA-N 0.000 description 2
- ITJNARMNRKSWTA-RLXJOQACSA-N 3-(2-methoxyphenoxy)-3-phenyl-n-(tritritiomethyl)propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC([3H])([3H])[3H])OC1=CC=CC=C1OC ITJNARMNRKSWTA-RLXJOQACSA-N 0.000 description 2
- ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 2
- 102000017910 Adrenergic receptor Human genes 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 229930182843 D-Lactic acid Natural products 0.000 description 2
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 2
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 206010037180 Psychiatric symptoms Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 206010005159 blepharospasm Diseases 0.000 description 2
- 230000000744 blepharospasm Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 230000002825 dopamine reuptake Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 229960004801 imipramine Drugs 0.000 description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 208000013433 lightheadedness Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 229960003955 mianserin Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000008450 motivation Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- 230000002474 noradrenergic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- CBQGYUDMJHNJBX-MOPGFXCFSA-N (2R)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine Chemical compound CCOC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-MOPGFXCFSA-N 0.000 description 1
- CBQGYUDMJHNJBX-RBUKOAKNSA-N (2s)-2-[(r)-(2-ethoxyphenoxy)-phenylmethyl]morpholine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@H]1OCCNC1 CBQGYUDMJHNJBX-RBUKOAKNSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 208000009233 Morning Sickness Diseases 0.000 description 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000034850 Vomiting in pregnancy Diseases 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- YTIVTFGABIZHHX-UHFFFAOYSA-L acetylenedicarboxylate(2-) Chemical compound [O-]C(=O)C#CC([O-])=O YTIVTFGABIZHHX-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000008503 anti depressant like effect Effects 0.000 description 1
- 230000000891 anti-reserpine Effects 0.000 description 1
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 1
- 229960002430 atomoxetine Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940030611 beta-adrenergic blocking agent Drugs 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000005257 cortical tissue Anatomy 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 229940022769 d- lactic acid Drugs 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- NELSQLPTEWCHQW-UHFFFAOYSA-N fezolamine Chemical compound N=1N(CCCN(C)C)C=C(C=2C=CC=CC=2)C=1C1=CC=CC=C1 NELSQLPTEWCHQW-UHFFFAOYSA-N 0.000 description 1
- 229950000761 fezolamine Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- KKLGDUSGQMHBPB-UHFFFAOYSA-N hex-2-ynedioic acid Chemical compound OC(=O)CCC#CC(O)=O KKLGDUSGQMHBPB-UHFFFAOYSA-N 0.000 description 1
- 230000000742 histaminergic effect Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960002672 isocarboxazid Drugs 0.000 description 1
- 208000028756 lack of coordination Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 229960002813 lofepramine Drugs 0.000 description 1
- SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000012154 norepinephrine uptake Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229940053544 other antidepressants in atc Drugs 0.000 description 1
- 208000020629 overactive bladder Diseases 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 210000005215 presynaptic neuron Anatomy 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 208000022610 schizoaffective disease Diseases 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000013275 serotonin uptake Effects 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 210000003568 synaptosome Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 231100000462 teratogen Toxicity 0.000 description 1
- 239000003439 teratogenic agent Substances 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000003569 transporter assay Methods 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 206010046494 urge incontinence Diseases 0.000 description 1
- 230000003202 urodynamic effect Effects 0.000 description 1
- 230000000980 vagolytic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002532330A CA2532330C (en) | 1999-07-01 | 2000-06-22 | Highly selective norepinephrine reuptake inhibitors and methods of using the same |
| CA002543986A CA2543986C (en) | 1999-07-01 | 2000-06-22 | Norepinephrine reuptake inhibitors and methods of using the same |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14196899P | 1999-07-01 | 1999-07-01 | |
| US60/141,968 | 1999-07-01 | ||
| US14413199P | 1999-07-16 | 1999-07-16 | |
| US60/144,131 | 1999-07-16 | ||
| US15825699P | 1999-10-06 | 1999-10-06 | |
| US60/158,256 | 1999-10-06 | ||
| US17038199P | 1999-12-13 | 1999-12-13 | |
| US60/170,381 | 1999-12-13 | ||
| PCT/US2000/017256 WO2001001973A2 (en) | 1999-07-01 | 2000-06-22 | Highly selective norepinephrine reuptake inhibitors and methods of using the same |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002543986A Division CA2543986C (en) | 1999-07-01 | 2000-06-22 | Norepinephrine reuptake inhibitors and methods of using the same |
| CA002532330A Division CA2532330C (en) | 1999-07-01 | 2000-06-22 | Highly selective norepinephrine reuptake inhibitors and methods of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2375908A1 CA2375908A1 (en) | 2001-01-11 |
| CA2375908C true CA2375908C (en) | 2006-05-30 |
Family
ID=27495506
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002375908A Expired - Fee Related CA2375908C (en) | 1999-07-01 | 2000-06-22 | Highly selective norepinephrine reuptake inhibitors and methods of using the same |
| CA002643231A Abandoned CA2643231A1 (en) | 1999-07-01 | 2000-06-22 | Norepinephrine reuptake inhibitors and methods of using the same |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002643231A Abandoned CA2643231A1 (en) | 1999-07-01 | 2000-06-22 | Norepinephrine reuptake inhibitors and methods of using the same |
Country Status (30)
| Country | Link |
|---|---|
| US (18) | US6465458B1 (enExample) |
| EP (3) | EP2090312A1 (enExample) |
| JP (3) | JP2003503450A (enExample) |
| KR (5) | KR20090087135A (enExample) |
| CN (5) | CN1205935C (enExample) |
| AR (1) | AR035158A1 (enExample) |
| AT (9) | ATE319453T1 (enExample) |
| AU (2) | AU771258B2 (enExample) |
| BR (1) | BR0012136A (enExample) |
| CA (2) | CA2375908C (enExample) |
| CL (3) | CL2008002866A1 (enExample) |
| CO (1) | CO5190662A1 (enExample) |
| CZ (1) | CZ299847B6 (enExample) |
| DE (9) | DE60020613T2 (enExample) |
| DK (4) | DK1459749T3 (enExample) |
| EA (6) | EA006652B1 (enExample) |
| ES (9) | ES2247572T3 (enExample) |
| GE (1) | GEP20094798B (enExample) |
| HU (1) | HUP0201623A3 (enExample) |
| IL (3) | IL147246A0 (enExample) |
| MX (1) | MXPA02000562A (enExample) |
| MY (1) | MY137348A (enExample) |
| NO (4) | NO20016406L (enExample) |
| NZ (2) | NZ533243A (enExample) |
| PE (1) | PE20010684A1 (enExample) |
| PL (1) | PL196996B1 (enExample) |
| PT (5) | PT1632234E (enExample) |
| SK (5) | SK286669B6 (enExample) |
| TW (9) | TWI298255B (enExample) |
| WO (1) | WO2001001973A2 (enExample) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003503450A (ja) * | 1999-07-01 | 2003-01-28 | ファルマシア・アンド・アップジョン・カンパニー | 高選択的ノルエピネフリン再取込みインヒビターおよびその使用方法 |
| YU37602A (sh) * | 1999-12-01 | 2005-07-19 | Ucb S.A. | Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns |
| DE60115872T2 (de) | 2000-04-21 | 2006-07-13 | Pharmacia & Upjohn Co. Llc, Kalamazoo | Cabergolin zur behandlung von fibromyalgie und chronic-fatigue-syndrom |
| BR0110188A (pt) * | 2000-04-21 | 2003-03-05 | Upjohn Co | Compostos selecionados para o tratamento de sìndromes de fibromialgia e de fadiga crÈnica |
| US20040048860A1 (en) * | 2000-10-31 | 2004-03-11 | Jes Olesen | Use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache |
| CA2426069A1 (en) * | 2000-11-15 | 2002-05-23 | David Michelson | Treatment of anxiety disorders |
| WO2002083141A1 (en) * | 2001-04-17 | 2002-10-24 | Pharmacia & Upjohn Company | Treatment of fibromyalgia and chronic fatigue syndrome |
| US20040048874A1 (en) * | 2001-05-22 | 2004-03-11 | Bardsley Hazel Judith | New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine |
| GB0216027D0 (en) * | 2002-07-10 | 2002-08-21 | Arachnova Therapeutics Ltd | New therapeutic use |
| US20060167074A1 (en) * | 2001-06-19 | 2006-07-27 | Norbert Muller | Methods and compositions for the treatment of psychiatric disorders |
| DE60234873D1 (de) * | 2001-06-19 | 2010-02-04 | Norbert Mueller | Verwendung von COX-2 Inhibitoren zur Behandlung von affectiven Störungen |
| US6602911B2 (en) | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
| AU2002347984A1 (en) * | 2001-11-30 | 2003-06-17 | Eli Lilly And Company | Use of norepinephrine reuptake inhibitors for the treatment of tic disorders |
| DE60223718T2 (de) * | 2001-12-11 | 2008-10-30 | Eli Lilly And Co., Indianapolis | Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen |
| US20040102440A1 (en) * | 2002-07-01 | 2004-05-27 | Wong Erik Ho Fong | Method of promoting smoking cessation |
| JP2005522445A (ja) * | 2002-02-12 | 2005-07-28 | サイプレス バイオサイエンス， インコーポレイテッド | 注意欠陥過活動性障害（ａｄ／ｈｄ）の処置方法 |
| CA2483093A1 (en) * | 2002-04-24 | 2003-11-06 | Cypress Bioscience, Inc. | Use of milnacipran or a pharmaceutically acceptable salt thereof for treating chronic low back pain |
| CA2483464C (en) * | 2002-05-17 | 2011-12-20 | Duke University | Method for treating obesity |
| ATE536874T1 (de) * | 2002-05-30 | 2011-12-15 | Neurosearch As | Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen |
| AU2003227755B2 (en) * | 2002-06-17 | 2009-01-15 | Pfizer Italia S.R.L. | Pharmaceutical salts of reboxetine |
| AR040680A1 (es) * | 2002-07-25 | 2005-04-13 | Pharmacia Corp | Composicion de tabletas de liberacion sostenida |
| US20050226926A1 (en) | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
| CA2495452A1 (en) * | 2002-08-14 | 2004-02-26 | Pharmacia & Upjohn Company Llc | Use of reboxetine for the treatment of hot flashes |
| GB0219687D0 (en) | 2002-08-23 | 2002-10-02 | Lilly Co Eli | Benzyl morpholine derivatives |
| US7294623B2 (en) | 2002-08-23 | 2007-11-13 | Eli Lilly And Company | Benzyl morpholine derivatives |
| EP1534291B1 (en) | 2002-08-23 | 2008-11-12 | Eli Lilly And Company | 2-(phenylthiomethyl)- morpholine derivatives for use as selective norepinephrine reuptake inhibitors |
| AU2003284005B2 (en) * | 2002-10-03 | 2009-12-17 | Forest Laboratories Holdings Limited | Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders |
| US20040152710A1 (en) * | 2002-10-15 | 2004-08-05 | Deecher Darlene Coleman | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| US7345096B2 (en) * | 2002-10-15 | 2008-03-18 | Wyeth | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| US20040180879A1 (en) * | 2002-10-15 | 2004-09-16 | Deecher Darlene Coleman | Novel method of treating vasomotor symptoms |
| US20040204411A1 (en) * | 2002-12-17 | 2004-10-14 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
| NZ541008A (en) * | 2003-01-13 | 2007-09-28 | Dynogen Pharmaceuticals Inc | Method of treating functional bowel disorders |
| NZ541009A (en) * | 2003-01-13 | 2007-09-28 | Dynogen Pharmaceuticals Inc | Method of treating nausea, vomiting, retching or any combination thereof |
| AU2004227945B2 (en) * | 2003-04-04 | 2006-10-26 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
| ES2639579T3 (es) | 2003-04-29 | 2017-10-27 | Orexigen Therapeutics, Inc. | Composiciones para afectar la pérdida de peso que comprende un antagonista opioide y bupropión |
| WO2004100929A1 (en) | 2003-05-12 | 2004-11-25 | Synergia Pharma, Inc. | Threo-dops controlled release formulation |
| US8158149B2 (en) * | 2004-05-12 | 2012-04-17 | Chelsea Therapeutics, Inc. | Threo-DOPS controlled release formulation |
| WO2004105690A2 (en) * | 2003-05-23 | 2004-12-09 | Cypress Bioscience, Inc. | Treatment of chronic pain associated with drug or radiation therapy |
| GB0319793D0 (en) * | 2003-08-22 | 2003-09-24 | Lilly Co Eli | Pyridinylmorpholine derivatives |
| EP1660065A2 (en) * | 2003-08-27 | 2006-05-31 | Eli Lilly And Company | Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors |
| WO2005025561A1 (en) * | 2003-09-04 | 2005-03-24 | Synergia Pharma, Inc. | Compositions and methods for orthostatic intolerance |
| WO2005025675A1 (en) * | 2003-09-12 | 2005-03-24 | Pfizer Limited | Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors |
| US7531543B2 (en) | 2003-10-14 | 2009-05-12 | Wyeth | Phenylpiperazine cycloalkanol derivatives and methods of their use |
| US7402698B2 (en) | 2003-10-14 | 2008-07-22 | Wyeth | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use |
| US20050130987A1 (en) * | 2003-10-14 | 2005-06-16 | Wyeth | Methods of treating vasomotor symptoms |
| US7419980B2 (en) | 2003-10-14 | 2008-09-02 | Wyeth | Fused-aryl and heteroaryl derivatives and methods of their use |
| US7524846B2 (en) | 2003-10-14 | 2009-04-28 | Wyeth | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use |
| US7550485B2 (en) | 2003-10-14 | 2009-06-23 | Wyeth | Substituted N-heterocycle derivatives and methods of their use |
| US7365076B2 (en) | 2003-10-14 | 2008-04-29 | Wyeth | Substituted aryl cycloalkanol derivatives and methods of their use |
| US7491723B2 (en) | 2003-10-14 | 2009-02-17 | Wyeth | Alkanol and cycloalkanol-amine derivatives and methods of their use |
| GB0326148D0 (en) | 2003-11-10 | 2003-12-17 | Lilly Co Eli | Morpholine derivatives |
| KR20060121178A (ko) * | 2003-12-12 | 2006-11-28 | 일라이 릴리 앤드 캄파니 | 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제 |
| WO2005066144A1 (en) * | 2003-12-23 | 2005-07-21 | Eli Lilly And Company | Morpholine derivatives as norepinephrine reuptake inhibitors |
| US7414052B2 (en) | 2004-03-30 | 2008-08-19 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
| US7517899B2 (en) * | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
| EA200601798A1 (ru) * | 2004-04-30 | 2007-04-27 | Уорнер-Ламберт Компани Ллс | Замещенные соединения морфолина для лечения расстройств центральной нервной системы |
| KR100871272B1 (ko) * | 2004-04-30 | 2008-11-28 | 화이자 인코포레이티드 | 모폴린 화합물 |
| GB0409744D0 (en) * | 2004-04-30 | 2004-06-09 | Pfizer Ltd | Novel compounds |
| EP1763354A2 (en) * | 2004-06-09 | 2007-03-21 | Pfizer Limited | Use of reboxetine for the treatment of pain |
| US7244765B2 (en) * | 2004-06-25 | 2007-07-17 | Cytokine Pharmasciences, Inc | Guanylhydrazone salts, compositions, processes of making and methods of using |
| US20090227562A1 (en) * | 2004-08-10 | 2009-09-10 | Pfizer Inc. | Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor |
| UA86831C2 (uk) | 2004-08-13 | 2009-05-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Композиція таблетки пролонгованого вивільнення, яка містить праміпексол або його фармацевтично прийнятну сіль, спосіб її виготовлення та її застосування |
| JP2008514689A (ja) * | 2004-10-01 | 2008-05-08 | ニューロキュア リミテッド | Ａｄｈｄ、ｃｆｓ、ｆｍおよび鬱病の処置のためのロフェプラミンの薬学的な組成物の使用 |
| US20060293309A1 (en) * | 2005-03-28 | 2006-12-28 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
| US7994220B2 (en) * | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
| JP5180092B2 (ja) | 2005-11-22 | 2013-04-10 | オレキシジェン・セラピューティクス・インコーポレーテッド | インスリン感受性を増すための組成物および方法 |
| US20070253994A1 (en) * | 2006-04-28 | 2007-11-01 | Medtronic, Inc. | Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| DK1948155T3 (da) * | 2006-06-28 | 2012-07-02 | Chelsea Therapeutics Inc | Farmaceutiske præparater omfattende droxidopa |
| CN101573103A (zh) | 2006-11-09 | 2009-11-04 | 奥雷西根治疗公司 | 用于施用重量减轻药物的单位剂量包装和方法 |
| ES2480966T3 (es) | 2007-03-09 | 2014-07-29 | Chelsea Therapeutics, Inc. | Droxidopa y composición farmacéutica de la misma para el tratamiento de la fibromialgia |
| WO2008122019A1 (en) * | 2007-04-02 | 2008-10-09 | Cypress Biosciences, Inc. | Improving the tolerability of both mirtazapine and reboxetine by using them in combination |
| EP2152074A4 (en) * | 2007-04-30 | 2011-07-27 | Adolor Corp | (-) - E-10-OH-NT COMPOSITIONS, METHODS OF SYNTHESIS AND USE |
| AU2008248382B2 (en) * | 2007-05-07 | 2013-07-18 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders |
| US8580776B2 (en) * | 2007-07-10 | 2013-11-12 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating neurodegenerating diseases |
| US20090233959A1 (en) * | 2008-02-19 | 2009-09-17 | Adolor Corporation | Beloxepin and analogs for the treatment of pain |
| US20090233957A1 (en) * | 2008-02-19 | 2009-09-17 | Adolor Corporation | (-)-beloxepin and methods for its synthesis and use |
| US8475823B2 (en) | 2008-04-18 | 2013-07-02 | Medtronic, Inc. | Baclofen formulation in a polyorthoester carrier |
| US8956642B2 (en) | 2008-04-18 | 2015-02-17 | Medtronic, Inc. | Bupivacaine formulation in a polyorthoester carrier |
| US20110144145A1 (en) | 2008-05-30 | 2011-06-16 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| JP5405571B2 (ja) | 2008-07-24 | 2014-02-05 | セラヴァンス， インコーポレーテッド | ３−（フェノキシフェニルメチル）ピロリジン化合物 |
| US20100069389A1 (en) * | 2008-09-06 | 2010-03-18 | Bionevia Pharmaceuticals, Inc. | Novel forms of reboxetine |
| WO2010044016A1 (en) * | 2008-10-17 | 2010-04-22 | Pfizer Limited | Novel uses for esreboxetine and racemic reboxetine |
| WO2010120910A1 (en) * | 2009-04-15 | 2010-10-21 | Theravance, Inc. | 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds |
| RU2535669C2 (ru) * | 2009-07-13 | 2014-12-20 | Тереванс, Инк. | 3-феноксиметилпирролидиновые соединения |
| JP5714580B2 (ja) | 2009-07-21 | 2015-05-07 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | ３−フェノキシメチルピロリジン化合物 |
| KR20120124423A (ko) | 2010-01-11 | 2012-11-13 | 오렉시젠 세러퓨틱스 인크. | 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법 |
| WO2012051103A1 (en) | 2010-10-11 | 2012-04-19 | Theravance, Inc. | Serotonin reuptake inhibitors |
| WO2012075239A1 (en) | 2010-12-03 | 2012-06-07 | Theravance, Inc. | Serotonin reuptake inhibitors |
| JP5880913B2 (ja) | 2011-05-17 | 2016-03-09 | 三郎 佐古田 | パーキンソン病の体幹症状（姿勢反射異常）の治療剤 |
| RS67076B1 (sr) | 2012-06-06 | 2025-08-29 | Nalpropion Pharmaceuticals Llc | Kompozicija za upotrebu u postupku lečenja prekomerne težine i gojaznosti kod pacijenata sa visokim kardiovaskularnim rizikom |
| US10526280B2 (en) | 2014-11-13 | 2020-01-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | (2-amino-4-(arylamino)phenyl carbamates |
| US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| WO2021113163A1 (en) * | 2019-12-03 | 2021-06-10 | Axsome Therapeutics, Inc. | Use of reboxetine to treat nervous system disorders |
| EP3693020A1 (en) * | 2019-02-08 | 2020-08-12 | Burmaster International Group GmbH | Potassium enriched topical formulations for pain relief and sleep aid |
| KR20220108122A (ko) * | 2019-12-03 | 2022-08-02 | 액섬 테라퓨틱스, 인크. | 신경계 장애 치료를 위한 레복세틴의 용도 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3797494A (en) | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
| US3742951A (en) | 1971-08-09 | 1973-07-03 | Alza Corp | Bandage for controlled release of vasodilators |
| US3996934A (en) | 1971-08-09 | 1976-12-14 | Alza Corporation | Medical bandage |
| US4031894A (en) | 1975-12-08 | 1977-06-28 | Alza Corporation | Bandage for transdermally administering scopolamine to prevent nausea |
| IL56369A (en) | 1978-01-20 | 1984-05-31 | Erba Farmitalia | Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them |
| US4465458A (en) * | 1980-03-19 | 1984-08-14 | Matsushita Electric Industrial Co., Ltd. | Apparatus for burning liquid fuel equipped with heating-type fuel vaporizer |
| GB8419683D0 (en) | 1984-08-02 | 1984-09-05 | Erba Farmitalia | 3-substituted derivatives of 1-amino-2-hydroxy-propane |
| GB2167407B (en) | 1984-11-22 | 1988-05-11 | Erba Farmitalia | Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof |
| US4596807A (en) | 1985-03-26 | 1986-06-24 | Serotonin Industries Of Charleston | Method and compositions for controlling pain, depression and sedation |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| PH30083A (en) | 1991-02-25 | 1996-12-27 | Lilly Co Eli | Treatment of lower urinary tract disorders |
| US5281624A (en) | 1991-09-27 | 1994-01-25 | Eli Lilly And Company | N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof |
| US5192751A (en) | 1992-07-24 | 1993-03-09 | Eli Lilly And Company | Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence |
| TW344661B (en) | 1993-11-24 | 1998-11-11 | Lilly Co Eli | Pharmaceutical composition for treatment of incontinence |
| IL111786A0 (en) | 1993-12-01 | 1995-01-24 | Max Planck Gesellschaft | Methods of promoting the survival and differentiation of subclasses of cholinergic and serotonergic neurons using fibroblast growth factor-5 |
| CA2134038C (en) * | 1994-06-16 | 1997-06-03 | David Taiwai Wong | Potentiation of drug response |
| ZA958725B (en) | 1994-10-20 | 1997-04-16 | Lilly Co Eli | Treatment of disorders with duloxetine |
| CZ296263B6 (cs) | 1996-03-25 | 2006-02-15 | Eli Lilly And Company | Farmaceutická kompozice pro lécení bolesti a jejípouzití |
| AU2587297A (en) | 1996-03-25 | 1997-10-17 | Eli Lilly And Company | Method for treating pain |
| US5914333A (en) * | 1996-07-31 | 1999-06-22 | Novo Nordisk A/S | Treatment of psychotic disorders |
| US6290986B1 (en) * | 1996-10-24 | 2001-09-18 | Pharmaceutical Applications Associates, Llc | Method and composition for transdermal administration of pharmacologic agents |
| US6572880B2 (en) * | 1996-10-24 | 2003-06-03 | Pharmaceutical Applications Associates Llc | Methods and transdermal compositions for pain relief |
| US6479074B2 (en) * | 1996-10-24 | 2002-11-12 | Pharmaceutical Applications Associates Llc | Methods and transdermal compositions for pain relief |
| WO1999011208A1 (en) | 1997-08-28 | 1999-03-11 | Williams C Donald | Method and composition for transdermal administration of pharmacologic agents |
| US20020015713A1 (en) * | 1996-10-24 | 2002-02-07 | Murdock Robert W. | Methods and transdermal compositions for pain relief |
| ES2125696T3 (es) | 1996-11-27 | 1999-03-01 | Pfleger R Chem Fab | Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales. |
| KR20000057548A (ko) | 1996-12-13 | 2000-09-25 | 알프레드 엘. 미첼슨 | 광학적 전송물질 및 결합재 |
| WO1998046227A1 (en) | 1997-04-11 | 1998-10-22 | Eli Lilly And Company | Composition for treating pain |
| US5942530A (en) | 1997-08-28 | 1999-08-24 | Eli Lilly And Company | Method for treating pain |
| US6622036B1 (en) * | 2000-02-09 | 2003-09-16 | Cns Response | Method for classifying and treating physiologic brain imbalances using quantitative EEG |
| UA56257C2 (uk) | 1997-09-23 | 2003-05-15 | Елі Ліллі Енд Компані | Спосіб лікування неадекватної визивної поведінки |
| UA57107C2 (uk) * | 1997-09-23 | 2003-06-16 | Елі Ліллі Енд Компані | Спосіб лікування розладу поведінки |
| AU9214498A (en) | 1997-09-23 | 1999-04-12 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
| AU9692898A (en) | 1997-10-17 | 1999-05-10 | Eli Lilly And Company | Potentiation of pharmaceuticals |
| CN1301164A (zh) * | 1998-04-09 | 2001-06-27 | 法玛西雅厄普约翰美国公司 | 神经病症的新疗法 |
| US6586427B2 (en) * | 1998-04-09 | 2003-07-01 | Pharmacia & Upjohn Company | Treatments for nervous disorders |
| IT1305322B1 (it) | 1998-04-23 | 2001-05-04 | Pharmacia & Upjohn Spa | Uso di reboxetina per il trattamento di disturbi nervosi |
| BR9909559A (pt) | 1998-05-08 | 2000-12-19 | Upjohn Co | Novas combinações de drogas |
| SK20012000A3 (sk) | 1998-06-29 | 2001-08-06 | Pharmaceuticals Applications Asociates, Llc | Transdermálny prostriedok na zmiernenie bolesti |
| US6331571B1 (en) * | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
| JP2003503450A (ja) * | 1999-07-01 | 2003-01-28 | ファルマシア・アンド・アップジョン・カンパニー | 高選択的ノルエピネフリン再取込みインヒビターおよびその使用方法 |
| GB2355191A (en) | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
| SE9904750D0 (sv) | 1999-12-23 | 1999-12-23 | Pharmacia & Upjohn Ab | New formulation, use and method |
| CN1396829A (zh) | 2000-02-24 | 2003-02-12 | 法玛西雅厄普约翰美国公司 | 新的药物联合形式 |
| US20050096349A1 (en) * | 2003-11-03 | 2005-05-05 | University Of Florida | Methods to prevent or ameliorate medication-, procedure-or stress-induced cognitive and speech dysfunction and methods to optimize cognitive and speech functioning |
-
2000
- 2000-06-22 JP JP2001507467A patent/JP2003503450A/ja active Pending
- 2000-06-22 EP EP09161068A patent/EP2090312A1/en not_active Withdrawn
- 2000-06-22 PT PT05111704T patent/PT1632234E/pt unknown
- 2000-06-22 KR KR1020097015714A patent/KR20090087135A/ko not_active Ceased
- 2000-06-22 AT AT04025513T patent/ATE319453T1/de not_active IP Right Cessation
- 2000-06-22 DK DK04013381T patent/DK1459749T3/da active
- 2000-06-22 AT AT05111704T patent/ATE364386T1/de not_active IP Right Cessation
- 2000-06-22 KR KR1020017016963A patent/KR100704319B1/ko not_active Expired - Fee Related
- 2000-06-22 DE DE60020613T patent/DE60020613T2/de not_active Expired - Lifetime
- 2000-06-22 ES ES04013383T patent/ES2247572T3/es not_active Expired - Lifetime
- 2000-06-22 DE DE60022692T patent/DE60022692T2/de not_active Expired - Lifetime
- 2000-06-22 ES ES05111704T patent/ES2285645T3/es not_active Expired - Lifetime
- 2000-06-22 ES ES00941659T patent/ES2258010T3/es not_active Expired - Lifetime
- 2000-06-22 GE GEAP200011110A patent/GEP20094798B/en unknown
- 2000-06-22 DE DE60023043T patent/DE60023043T2/de not_active Expired - Lifetime
- 2000-06-22 WO PCT/US2000/017256 patent/WO2001001973A2/en not_active Ceased
- 2000-06-22 PT PT00941659T patent/PT1196172E/pt unknown
- 2000-06-22 DK DK00941659T patent/DK1196172T3/da active
- 2000-06-22 SK SK50024-2007A patent/SK286669B6/sk not_active IP Right Cessation
- 2000-06-22 CN CNB008084858A patent/CN1205935C/zh not_active Expired - Fee Related
- 2000-06-22 AT AT04023888T patent/ATE305306T1/de not_active IP Right Cessation
- 2000-06-22 SK SK1938-2001A patent/SK286104B6/sk not_active IP Right Cessation
- 2000-06-22 MX MXPA02000562A patent/MXPA02000562A/es active IP Right Grant
- 2000-06-22 CZ CZ20014625A patent/CZ299847B6/cs not_active IP Right Cessation
- 2000-06-22 EA EA200400589A patent/EA006652B1/ru not_active IP Right Cessation
- 2000-06-22 EA EA200700232A patent/EA011094B1/ru not_active IP Right Cessation
- 2000-06-22 DE DE60019473T patent/DE60019473T2/de not_active Expired - Lifetime
- 2000-06-22 BR BR0012136-3A patent/BR0012136A/pt not_active Application Discontinuation
- 2000-06-22 AT AT04013382T patent/ATE296634T1/de not_active IP Right Cessation
- 2000-06-22 ES ES04013381T patent/ES2246485T3/es not_active Expired - Lifetime
- 2000-06-22 EA EA200501496A patent/EA008381B1/ru not_active IP Right Cessation
- 2000-06-22 EP EP00941659A patent/EP1196172B1/en not_active Expired - Lifetime
- 2000-06-22 DE DE60022917T patent/DE60022917T2/de not_active Expired - Fee Related
- 2000-06-22 KR KR1020057009371A patent/KR100717660B1/ko not_active Expired - Fee Related
- 2000-06-22 SK SK50023-2007A patent/SK286668B6/sk not_active IP Right Cessation
- 2000-06-22 ES ES04013379T patent/ES2239311T3/es not_active Expired - Lifetime
- 2000-06-22 EA EA200200111A patent/EA005029B1/ru not_active IP Right Cessation
- 2000-06-22 AT AT04013383T patent/ATE304358T1/de not_active IP Right Cessation
- 2000-06-22 AT AT00941659T patent/ATE320257T1/de not_active IP Right Cessation
- 2000-06-22 ES ES04025514T patent/ES2246488T3/es not_active Expired - Lifetime
- 2000-06-22 DK DK05111704T patent/DK1632234T3/da active
- 2000-06-22 CA CA002375908A patent/CA2375908C/en not_active Expired - Fee Related
- 2000-06-22 PT PT04013379T patent/PT1459748E/pt unknown
- 2000-06-22 AT AT04013381T patent/ATE305788T1/de not_active IP Right Cessation
- 2000-06-22 CA CA002643231A patent/CA2643231A1/en not_active Abandoned
- 2000-06-22 DE DE60026627T patent/DE60026627T2/de not_active Expired - Fee Related
- 2000-06-22 KR KR1020097015713A patent/KR100948757B1/ko not_active Expired - Fee Related
- 2000-06-22 US US09/599,213 patent/US6465458B1/en not_active Expired - Lifetime
- 2000-06-22 EP EP09161069A patent/EP2087892A3/en not_active Withdrawn
- 2000-06-22 KR KR1020067017835A patent/KR100935277B1/ko not_active Expired - Fee Related
- 2000-06-22 CN CN2004101045241A patent/CN1660110A/zh active Pending
- 2000-06-22 NZ NZ533243A patent/NZ533243A/en unknown
- 2000-06-22 AT AT04025514T patent/ATE305307T1/de not_active IP Right Cessation
- 2000-06-22 PT PT04013382T patent/PT1459750E/pt unknown
- 2000-06-22 ES ES04013382T patent/ES2242175T3/es not_active Expired - Lifetime
- 2000-06-22 NZ NZ515885A patent/NZ515885A/en unknown
- 2000-06-22 SK SK50022-2007A patent/SK286864B6/sk not_active IP Right Cessation
- 2000-06-22 DK DK04013382T patent/DK1459750T3/da active
- 2000-06-22 PL PL352252A patent/PL196996B1/pl not_active IP Right Cessation
- 2000-06-22 ES ES04025513T patent/ES2258251T3/es not_active Expired - Lifetime
- 2000-06-22 SK SK50021-2007A patent/SK286667B6/sk not_active IP Right Cessation
- 2000-06-22 HU HU0201623A patent/HUP0201623A3/hu unknown
- 2000-06-22 AU AU56337/00A patent/AU771258B2/en not_active Ceased
- 2000-06-22 CN CNB2004101045256A patent/CN1289090C/zh not_active Expired - Fee Related
- 2000-06-22 DE DE60026704T patent/DE60026704T2/de not_active Expired - Lifetime
- 2000-06-22 AT AT04013379T patent/ATE292971T1/de not_active IP Right Cessation
- 2000-06-22 DE DE60022916T patent/DE60022916T2/de not_active Expired - Fee Related
- 2000-06-22 DE DE60035232T patent/DE60035232T2/de not_active Expired - Lifetime
- 2000-06-22 EA EA200801806A patent/EA200801806A1/ru unknown
- 2000-06-22 IL IL14724600A patent/IL147246A0/xx not_active IP Right Cessation
- 2000-06-22 PT PT04013383T patent/PT1459751E/pt unknown
- 2000-06-22 EA EA200801805A patent/EA200801805A1/ru unknown
- 2000-06-22 CN CN2004101045237A patent/CN1660109A/zh active Pending
- 2000-06-22 CN CN2004101045222A patent/CN1660108A/zh active Pending
- 2000-06-22 ES ES04023888T patent/ES2246487T3/es not_active Expired - Lifetime
- 2000-06-27 MY MYPI20002899A patent/MY137348A/en unknown
- 2000-06-28 PE PE2000000664A patent/PE20010684A1/es not_active Application Discontinuation
- 2000-06-30 AR ARP000103350A patent/AR035158A1/es unknown
- 2000-07-04 CO CO00049691A patent/CO5190662A1/es not_active Application Discontinuation
- 2000-09-05 TW TW094142128A patent/TWI298255B/zh not_active IP Right Cessation
- 2000-09-05 TW TW089113086A patent/TWI245631B/zh not_active IP Right Cessation
- 2000-09-05 TW TW097124378A patent/TW200922594A/zh unknown
- 2000-09-05 TW TW097124426A patent/TW200914027A/zh unknown
- 2000-09-05 TW TW094142131A patent/TWI294779B/zh active
- 2000-09-05 TW TW092137686A patent/TW200407146A/zh unknown
- 2000-09-05 TW TW094142132A patent/TWI293250B/zh active
- 2000-09-05 TW TW094142126A patent/TWI298254B/zh not_active IP Right Cessation
- 2000-09-05 TW TW097124457A patent/TW200920378A/zh unknown
-
2001
- 2001-12-14 US US10/020,261 patent/US6703389B2/en not_active Expired - Fee Related
- 2001-12-28 NO NO20016406A patent/NO20016406L/no unknown
-
2002
- 2002-01-04 US US10/099,334 patent/US6642235B2/en not_active Expired - Fee Related
- 2002-01-04 US US10/037,344 patent/US6610690B2/en not_active Expired - Lifetime
- 2002-01-23 US US10/055,663 patent/US6987107B2/en not_active Expired - Fee Related
- 2002-09-26 US US10/255,450 patent/US20030040464A1/en not_active Abandoned
-
2003
- 2003-09-24 US US10/669,611 patent/US20040058925A1/en not_active Abandoned
-
2004
- 2004-01-16 US US10/758,864 patent/US7317011B2/en not_active Expired - Fee Related
- 2004-05-18 AU AU2004202096A patent/AU2004202096B2/en not_active Ceased
-
2006
- 2006-02-07 US US11/349,022 patent/US7241762B2/en not_active Expired - Fee Related
- 2006-02-07 US US11/349,373 patent/US7276503B2/en not_active Expired - Fee Related
- 2006-02-07 US US11/348,948 patent/US20060142289A1/en not_active Abandoned
- 2006-02-07 US US11/349,331 patent/US7338953B2/en not_active Expired - Fee Related
- 2006-02-22 JP JP2006045459A patent/JP2006143749A/ja active Pending
- 2006-07-28 US US11/460,775 patent/US20060264436A1/en not_active Abandoned
- 2006-08-02 JP JP2006210418A patent/JP2006321815A/ja active Pending
-
2007
- 2007-10-30 US US11/928,917 patent/US7723334B2/en not_active Expired - Fee Related
- 2007-10-30 US US11/928,812 patent/US20080096890A1/en not_active Abandoned
- 2007-10-30 US US11/928,980 patent/US20080103147A1/en not_active Abandoned
- 2007-10-30 US US11/928,781 patent/US20080103145A1/en not_active Abandoned
- 2007-11-20 IL IL187513A patent/IL187513A0/en unknown
- 2007-11-20 IL IL187512A patent/IL187512A0/en unknown
-
2008
- 2008-09-26 CL CL2008002866A patent/CL2008002866A1/es unknown
- 2008-09-26 CL CL2008002867A patent/CL2008002867A1/es unknown
- 2008-09-26 CL CL2008002868A patent/CL2008002868A1/es unknown
-
2009
- 2009-03-18 NO NO20091168A patent/NO20091168L/no not_active Application Discontinuation
- 2009-03-18 NO NO20091158A patent/NO20091158L/no unknown
- 2009-03-18 NO NO20091159A patent/NO20091159L/no unknown
- 2009-04-27 US US12/430,244 patent/US20090247528A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2375908C (en) | Highly selective norepinephrine reuptake inhibitors and methods of using the same | |
| EP1493442A1 (en) | Reboxetine for treating peripheral neuropathy | |
| CA2532330C (en) | Highly selective norepinephrine reuptake inhibitors and methods of using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20160622 |